$63.03 3.1%
Price vs. AI Score (Last 150 days)
Data gathered: December 6

Data Bits

Data Bits Value / Change Benchmark
Job Posts 38 5.6%
Sentiment 73 -2.7%
Webpage traffic 32,000 60.3%
Employee Rating 92 0%
Google Trends 35 66.7%
Linkedin Employees 768 N/A
Patents 59 0%
4chan Mentions 0%
Facebook Engagement 144 14.3%
Facebook followers 6,656 -0%
Stocktwits Mentions 1 0%
Stocktwits Subscribers 765 -0.1%
Twitter Followers 1,582 0.1%
Instagram Followers 2,469 0%
News Mentions 0%
Reddit Mentions 0%
Business outlook 82 0%

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

In the news


About Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.


Glaukos
Price $63.03
Target Price Sign up
Market Cap $3.17B
Dividend Yield 0
Industry Medical Devices

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda
Q3 '2375M73M60M-30M-21M
Q2 '2377M73M60M-33M-23M
Q1 '2371M78M56M-35M-25M
Q4 '2271M69M54M-31M-19M
Q3 '2268M64M54M-28M-18M

Insider Transactions

Burns Thomas William filed to sell 54,785 shares at $74.4.
October 4 '23
Kliman Gilbert H filed to sell 29,725 shares at $74.6.
August 8 '23
Burns Thomas William filed to sell 673,963 shares at $80.
July 21 '23
Burns Thomas William filed to sell 673,963 shares at $79.7.
July 18 '23
Gilliam Joseph E filed to sell 120,484 shares at $78.3.
July 18 '23
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2023 AltIndex. All rights reserved.